Business Description
Catalyst Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US14888U1016
Description
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 38.69 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 15.06 | |||||
| Beneish M-Score | 0.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 46.2 | |||||
| 3-Year EBITDA Growth Rate | 39.2 | |||||
| 3-Year EPS without NRI Growth Rate | -6.1 | |||||
| 3-Year FCF Growth Rate | 8.7 | |||||
| 3-Year Book Growth Rate | 30.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 16.39 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.24 | |||||
| 9-Day RSI | 42.28 | |||||
| 14-Day RSI | 44.08 | |||||
| 6-1 Month Momentum % | 17.19 | |||||
| 12-1 Month Momentum % | -1.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.88 | |||||
| Quick Ratio | 2.68 | |||||
| Cash Ratio | 1.81 | |||||
| Days Inventory | 73.84 | |||||
| Days Sales Outstanding | 34.5 | |||||
| Days Payable | 43.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.1 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.95 | |||||
| Operating Margin % | 21.8 | |||||
| Net Margin % | 17.93 | |||||
| FCF Margin % | 15.53 | |||||
| ROE % | 20.45 | |||||
| ROA % | 16.92 | |||||
| ROIC % | 32.93 | |||||
| ROC (Joel Greenblatt) % | 894.1 | |||||
| ROCE % | 23.99 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.41 | |||||
| Forward PE Ratio | 10.13 | |||||
| PE Ratio without NRI | 24.41 | |||||
| Shiller PE Ratio | 108.69 | |||||
| Price-to-Owner-Earnings | 136.61 | |||||
| PS Ratio | 4.18 | |||||
| PB Ratio | 4.11 | |||||
| Price-to-Tangible-Book | 8.23 | |||||
| Price-to-Free-Cash-Flow | 28.42 | |||||
| Price-to-Operating-Cash-Flow | 11.55 | |||||
| EV-to-EBIT | 18.7 | |||||
| EV-to-Forward-EBIT | 8.7 | |||||
| EV-to-EBITDA | 13.56 | |||||
| EV-to-Revenue | 4.08 | |||||
| EV-to-Forward-Revenue | 3.51 | |||||
| EV-to-FCF | 26.24 | |||||
| Price-to-Projected-FCF | 2.27 | |||||
| Price-to-Graham-Number | 2.99 | |||||
| Price-to-Net-Current-Asset-Value | 11.63 | |||||
| Price-to-Net-Cash | 28.63 | |||||
| Earnings Yield (Greenblatt) % | 5.35 | |||||
| FCF Yield % | 3.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CPRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Catalyst Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 398.204 | ||
| EPS (TTM) ($) | 0.61 | ||
| Beta | 0.89 | ||
| Volatility % | 49.34 | ||
| 14-Day RSI | 44.08 | ||
| 14-Day ATR ($) | 0.584095 | ||
| 20-Day SMA ($) | 15.3455 | ||
| 12-1 Month Momentum % | -1.69 | ||
| 52-Week Range ($) | 11.09 - 17.765 | ||
| Shares Outstanding (Mil) | 118.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalyst Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Catalyst Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Catalyst Pharmaceuticals Inc Frequently Asked Questions
What is Catalyst Pharmaceuticals Inc(CPRX)'s stock price today?
The current price of CPRX is $14.89. The 52 week high of CPRX is $17.77 and 52 week low is $11.09.
When is next earnings date of Catalyst Pharmaceuticals Inc(CPRX)?
The next earnings date of Catalyst Pharmaceuticals Inc(CPRX) is 2024-05-08.
Does Catalyst Pharmaceuticals Inc(CPRX) pay dividends? If so, how much?
Catalyst Pharmaceuticals Inc(CPRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers